Merck Global Health Innovation Fund, an evolving corporate healthcare venture capital fund, and ARTIS Ventures, a financial services firm that finances early-to-late stage venture investments, led a $32m Series A funding round in Unnatural Products, a biotech company pairing AI with chemistry to usher in the next generation of molecularly targeted therapeutics, with participation from First Spark Ventures, The Venture Collective, Humain Ventures, LongeVC, and Not Boring Capital. “We’re very fortunate to have the support from MGHIF and ARTIS and great new investors added to the roster in this round. This underlines our team’s hard work building a platform to accelerate this burgeoning molecular class. Macrocycles are today where antibody therapeutics were a couple of decades ago. We finally have the technologies to rapidly and reproducibly find and optimize macrocycles against any given target. I believe macrocycles will be as impactful to the pharmaceutical industry as the biologics revolution of the early 2000s," Cameron Pye, Unnatural Products CEO and Co-Founder.